US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
GB9824544D0
(en)
*
|
1998-11-09 |
1999-01-06 |
Medical Res Council |
Screening system
|
US7262055B2
(en)
|
1998-08-25 |
2007-08-28 |
Gendaq Limited |
Regulated gene expression in plants
|
USRE45721E1
(en)
|
1994-08-20 |
2015-10-06 |
Gendaq, Ltd. |
Relating to binding proteins for recognition of DNA
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
US6410248B1
(en)
|
1998-01-30 |
2002-06-25 |
Massachusetts Institute Of Technology |
General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
|
JP4309051B2
(en)
|
1998-03-02 |
2009-08-05 |
マサチューセッツ インスティテュート オブ テクノロジー |
Polyzinc finger protein with improved linker
|
AU751487B2
(en)
*
|
1998-03-17 |
2002-08-15 |
Gendaq Limited |
Nucleic acid binding proteins
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6503717B2
(en)
|
1999-12-06 |
2003-01-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
US7943731B1
(en)
|
1999-08-11 |
2011-05-17 |
Massachusetts Institute Of Technology |
Dimerizing peptides
|
AU2001226935B2
(en)
|
2000-01-24 |
2006-06-22 |
Gendaq Limited |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
US7923542B2
(en)
|
2000-04-28 |
2011-04-12 |
Sangamo Biosciences, Inc. |
Libraries of regulatory sequences, methods of making and using same
|
ATE374249T1
(en)
|
2000-04-28 |
2007-10-15 |
Sangamo Biosciences Inc |
DATABASES OF REGULATORY SEQUENCES, METHODS OF THEIR PRODUCTION AND USE
|
WO2001084148A2
(en)
|
2000-04-28 |
2001-11-08 |
Sangamo Biosciences, Inc. |
Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
|
AU2001257331A1
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
WO2001085780A2
(en)
*
|
2000-05-08 |
2001-11-15 |
Gendaq Limited |
Nucleic acid binding polypeptides
|
AU2001278496A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Syngenta Participations Ag |
Zinc finger domain recognition code and uses thereof
|
WO2002018648A2
(en)
*
|
2000-08-25 |
2002-03-07 |
President And Fellows Of Harvard College |
Analysis of binding interactions
|
US6905816B2
(en)
|
2000-11-27 |
2005-06-14 |
Intelligent Medical Devices, Inc. |
Clinically intelligent diagnostic devices and methods
|
EP1341914A2
(en)
|
2000-12-07 |
2003-09-10 |
Sangamo Biosciences Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7067317B2
(en)
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
CA2435394C
(en)
|
2001-01-22 |
2018-01-09 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
US7947469B2
(en)
|
2001-01-22 |
2011-05-24 |
Gendaq, Ltd. |
Modulation of HIV infection
|
CA2461290C
(en)
|
2001-09-24 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
US7262054B2
(en)
|
2002-01-22 |
2007-08-28 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
AU2003251286B2
(en)
|
2002-01-23 |
2007-08-16 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
DK2348119T3
(en)
|
2002-02-01 |
2017-08-21 |
Oxford Biomedica (Uk) Ltd |
Polycistronic lentiviral vector
|
EP2036984B1
(en)
|
2002-07-26 |
2012-02-22 |
BASF Plant Science GmbH |
Reversion of the negative selective effect of negative marker proteins as selection procedure
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
AU2003298574B2
(en)
|
2002-09-05 |
2008-04-24 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
GB0228289D0
(en)
|
2002-12-04 |
2003-01-08 |
Genome Inst Of Singapore Nat U |
Method
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
EP2927318B1
(en)
|
2003-08-08 |
2020-05-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
WO2005028630A2
(en)
|
2003-09-19 |
2005-03-31 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
AU2005233583B2
(en)
|
2004-04-08 |
2011-02-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating cardiac contractility
|
US20050282193A1
(en)
|
2004-04-23 |
2005-12-22 |
Bulyk Martha L |
Space efficient polymer sets
|
WO2006033859A2
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
WO2006094106A2
(en)
|
2005-02-28 |
2006-09-08 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
CA2615532C
(en)
|
2005-07-26 |
2016-06-28 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
JP5266210B2
(en)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Modified cleavage half-domain
|
CA2651499C
(en)
|
2006-05-25 |
2015-06-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for ccr-5 gene inactivation
|
EP2395081A1
(en)
|
2006-08-11 |
2011-12-14 |
Dow AgroSciences LLC |
Zinc finger nuclease-mediated homologous recombination
|
WO2008060510A2
(en)
*
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
TWI470079B
(en)
|
2006-12-14 |
2015-01-21 |
Dow Agrosciences Llc |
Optimized non-canonical zinc finger proteins
|
AU2008244473B2
(en)
|
2007-04-26 |
2013-06-20 |
Sangamo Therapeutics, Inc. |
Targeted integration into the PPP1R12C locus
|
WO2009009086A2
(en)
|
2007-07-12 |
2009-01-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
KR101657504B1
(en)
|
2007-09-27 |
2016-09-19 |
상가모 바이오사이언스 인코포레이티드 |
Rapid in vivo identification of biologically active nucleases
|
HUE029916T2
(en)
|
2007-09-27 |
2017-04-28 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
CA2703045C
(en)
|
2007-10-25 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
AU2009238629C1
(en)
|
2008-04-14 |
2015-04-30 |
Sangamo Therapeutics, Inc. |
Linear donor constructs for targeted integration
|
CN104263751A
(en)
|
2008-04-21 |
2015-01-07 |
丹齐格创新有限公司 |
Plant Viral Expression Vectors And Use Of Same For Generating Genotypic Variations In Plant Genomes
|
KR101598867B1
(en)
|
2008-04-30 |
2016-03-03 |
산바이오 인코포레이티드 |
Neural regenerating cells with alterations in dna methylation
|
JP2011521643A
(en)
|
2008-05-28 |
2011-07-28 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Composition for linking a DNA binding domain and a cleavage domain
|
CA2893175C
(en)
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
AU2009283194B2
(en)
|
2008-08-22 |
2014-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
US8153399B2
(en)
|
2008-10-29 |
2012-04-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
CA2745031C
(en)
|
2008-12-04 |
2018-08-14 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
AR074783A1
(en)
|
2008-12-17 |
2011-02-09 |
Dow Agrosciences Llc |
METHODS AND COMPOSITIONS TO EXPRESS ONE OR MORE PRODUCTS OF A NUCLEIC ACID INTEGRATED TO LOCUS ZP15 OF A VEGETABLE CELL
|
AU2010211057B2
(en)
|
2009-02-04 |
2014-12-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathies
|
US8871905B2
(en)
|
2009-03-20 |
2014-10-28 |
Sangamo Biosciences, Inc. |
Modification of CXCR4 using engineered zinc finger proteins
|
JP6215533B2
(en)
|
2009-04-09 |
2017-10-18 |
サンガモ セラピューティクス, インコーポレイテッド |
Targeted integration into stem cells
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
AU2010266705B2
(en)
|
2009-06-30 |
2014-06-05 |
Sangamo Therapeutics, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
WO2011016840A2
(en)
|
2009-07-28 |
2011-02-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
EP2462230B1
(en)
|
2009-08-03 |
2015-07-15 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
US20110041195A1
(en)
|
2009-08-11 |
2011-02-17 |
Sangamo Biosciences, Inc. |
Organisms homozygous for targeted modification
|
US9476060B2
(en)
|
2009-10-21 |
2016-10-25 |
Danziger Innovations Ltd. |
Generating genotypic variations in plant genomes by gamete infection
|
UA120742C2
(en)
|
2009-10-22 |
2020-02-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
CONSTRUCTED PROTEIN WITH ZINC FINGERS AIMED AT PLANT GENES INVOLVED IN FATTY ACID BIOSYNTHESIS
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
AU2010325549B2
(en)
|
2009-11-27 |
2017-04-20 |
Basf Plant Science Company Gmbh |
Optimized endonucleases and uses thereof
|
NZ601247A
(en)
|
2010-01-22 |
2014-10-31 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
WO2011097036A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
EP2534163B1
(en)
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
WO2011139335A1
(en)
|
2010-04-26 |
2011-11-10 |
Sangamo Biosciences, Inc. |
Genome editing of a rosa locus using zinc-finger nucleases
|
EP3636766A1
(en)
|
2010-05-03 |
2020-04-15 |
Sangamo Therapeutics, Inc. |
Compositions for linking zinc finger modules
|
CN103025344B
(en)
|
2010-05-17 |
2016-06-29 |
桑格摩生物科学股份有限公司 |
Novel DNA-associated proteins and application thereof
|
WO2012012667A2
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a hla locus
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
AU2011316575B2
(en)
|
2010-10-12 |
2015-10-29 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia B
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
EP2694554A1
(en)
|
2011-04-08 |
2014-02-12 |
Gilead Biologics, Inc. |
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
EP2737063B1
(en)
|
2011-07-25 |
2016-06-01 |
Sangamo BioSciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
EP2758529B1
(en)
|
2011-09-21 |
2019-03-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
JP6144691B2
(en)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
Modified DNA binding proteins and uses thereof
|
CA2862309A1
(en)
|
2012-01-27 |
2013-08-01 |
Sanbio, Inc. |
Methods and compositions for modulating angiogenesis and vasculogenesis
|
AU2013225950B2
(en)
|
2012-02-29 |
2018-02-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating huntington's disease
|
EP3839050A3
(en)
|
2012-04-18 |
2021-09-29 |
The Board of Trustees of the Leland Stanford Junior University |
Non-disruptive gene targeting
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
EP2844754B1
(en)
|
2012-05-02 |
2018-10-24 |
Dow AgroSciences LLC |
Targeted modification of malate dehydrogenase
|
RU2650819C2
(en)
|
2012-05-07 |
2018-04-17 |
Сангамо Терапьютикс, Инк. |
Methods and compositions for nuclease-mediated targeting of transgenes
|
WO2013169398A2
(en)
|
2012-05-09 |
2013-11-14 |
Georgia Tech Research Corporation |
Systems and methods for improving nuclease specificity and activity
|
US9877988B2
(en)
|
2012-07-11 |
2018-01-30 |
Sangamo Therapeutics, Inc. |
Method of treating lysosomal storage diseases using nucleases and a transgene
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
SG10201701601WA
(en)
|
2012-08-29 |
2017-04-27 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
NZ705745A
(en)
|
2012-09-07 |
2018-11-30 |
Sangamo Biosciences Inc |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
WO2014089212A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
JP2016500268A
(en)
|
2012-12-13 |
2016-01-12 |
ダウ アグロサイエンシィズ エルエルシー |
Precise gene targeting for specific loci in maize
|
JP6491113B2
(en)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
EP2981166B1
(en)
|
2013-04-05 |
2020-09-09 |
Dow AgroSciences LLC |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US9567609B2
(en)
|
2013-08-28 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
EP3058072B1
(en)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
EP3057432B1
(en)
|
2013-10-17 |
2018-11-21 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
UA120503C2
(en)
|
2013-11-04 |
2019-12-26 |
Дау Агросайєнсиз Елелсі |
Optimal maize loci
|
MX358066B
(en)
|
2013-11-04 |
2018-08-03 |
Dow Agrosciences Llc |
Optimal soybean loci.
|
WO2015066638A2
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal maize loci
|
CA2926822C
(en)
|
2013-11-04 |
2022-12-13 |
Dow Agrosciences Llc |
Optimal soybean loci
|
AU2014346424B2
(en)
|
2013-11-11 |
2020-09-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
EP3492593B1
(en)
|
2013-11-13 |
2021-08-18 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
AU2014364051B2
(en)
|
2013-12-09 |
2018-12-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
WO2015117081A2
(en)
|
2014-02-03 |
2015-08-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
MX2016011690A
(en)
|
2014-03-21 |
2016-11-07 |
Univ Leland Stanford Junior |
Genome editing without nucleases.
|
US10507232B2
(en)
|
2014-04-02 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
CN106413760B
(en)
|
2014-05-08 |
2020-01-14 |
桑格摩生物科学股份有限公司 |
Methods and compositions for treating huntington's disease
|
EP3721875B1
(en)
|
2014-05-09 |
2023-11-08 |
Yale University |
Particles coated with hyperbranched polyglycerol and methods for their preparation
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
CA2947622A1
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Genome editing methods and compositions for prevention or treatment of a disease
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
EP3166964A1
(en)
|
2014-07-08 |
2017-05-17 |
Vib Vzw |
Means and methods to increase plant yield
|
PT3169778T
(en)
|
2014-07-14 |
2024-01-29 |
Univ Washington State |
Nanos knock-out that ablates germline cells
|
WO2016011210A2
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
WO2016011381A1
(en)
|
2014-07-18 |
2016-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
KR20170054445A
(en)
|
2014-09-16 |
2017-05-17 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
WO2016118726A2
(en)
|
2015-01-21 |
2016-07-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for identification of highly specific nucleases
|
SG10202101358XA
(en)
|
2015-01-26 |
2021-03-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
JP6929791B2
(en)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
Compositions and methods for epigenome editing
|
AU2016243052C1
(en)
|
2015-04-03 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of B-cells
|
BR112017021703B1
(en)
|
2015-04-15 |
2023-11-28 |
Corteva Agriscience Llc |
PLANT PROMOTER FOR TRANSGENE EXPRESSION
|
CN107614690A
(en)
|
2015-04-15 |
2018-01-19 |
美国陶氏益农公司 |
Plant promoter for transgene expression
|
CN108026566A
(en)
|
2015-05-04 |
2018-05-11 |
特拉维夫大学拉莫特有限公司 |
For making the method and kit of DNA fragmentation
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
MX2017014446A
(en)
|
2015-05-12 |
2018-06-13 |
Sangamo Therapeutics Inc |
Nuclease-mediated regulation of gene expression.
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
MX2018001529A
(en)
|
2015-08-06 |
2018-04-24 |
Univ Missouri |
Pathogen-resistant animals having modified cd163 genes.
|
TW201718862A
(en)
|
2015-09-22 |
2017-06-01 |
Dow Agrosciences Llc |
Plant promoter and 3' UTR for transgene expression
|
TW201718861A
(en)
|
2015-09-22 |
2017-06-01 |
道禮責任有限公司 |
Plant promoter and 3'UTR for transgene expression
|
JP6853257B2
(en)
|
2015-09-23 |
2021-03-31 |
サンガモ セラピューティクス, インコーポレイテッド |
HTT repressor and its use
|
EP3365451B1
(en)
|
2015-10-22 |
2020-06-24 |
Dow Agrosciences LLC |
Plant promoter for transgene expression
|
WO2017078807A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
WO2017078935A1
(en)
|
2015-11-04 |
2017-05-11 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
CN115806940A
(en)
|
2015-11-04 |
2023-03-17 |
菲特治疗公司 |
Genome engineering of pluripotent cells
|
CA3004349A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
KR20180088911A
(en)
|
2015-12-18 |
2018-08-07 |
상가모 테라퓨틱스, 인코포레이티드 |
Targeted Collapse of MHC Cell Receptors
|
CN108778297B
(en)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
Targeted disruption of T cell receptors
|
JP6930052B2
(en)
|
2016-01-15 |
2021-09-01 |
サンガモ セラピューティクス, インコーポレイテッド |
Methods and compositions for the treatment of neurological disorders
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
AU2017221405A1
(en)
|
2016-02-16 |
2018-09-20 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
CA3014795A1
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
US11421218B2
(en)
|
2016-03-23 |
2022-08-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
EP3448997B1
(en)
|
2016-04-27 |
2020-10-14 |
Massachusetts Institute of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
CN110291402B
(en)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
Method for identifying peptide epitopes, molecules binding such epitopes and related uses
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
CN114652735A
(en)
|
2016-07-27 |
2022-06-24 |
凯斯西储大学 |
Compounds and methods for promoting myelination
|
EP3497213B1
(en)
|
2016-08-09 |
2023-10-18 |
Vib Vzw |
Cellulose synthase inhibitors and mutant plants
|
PL3504229T3
(en)
|
2016-08-24 |
2022-04-19 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
US10975393B2
(en)
|
2016-08-24 |
2021-04-13 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
US10400246B2
(en)
|
2016-10-03 |
2019-09-03 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
CA3038520A1
(en)
|
2016-10-03 |
2018-04-12 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
CN110050061A
(en)
|
2016-10-05 |
2019-07-23 |
富士胶片细胞动力公司 |
The mature pedigree of generation is induced multi-potent stem cell from what is destroyed with MeCP2
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
JP7042263B2
(en)
|
2016-10-20 |
2022-03-25 |
サンガモ セラピューティクス, インコーポレイテッド |
Methods and compositions for the treatment of Fabry disease
|
WO2018081138A1
(en)
|
2016-10-24 |
2018-05-03 |
Yale University |
Biodegradable contraceptive implants
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
JP7292204B2
(en)
|
2016-12-01 |
2023-06-16 |
サンガモ セラピューティクス, インコーポレイテッド |
Tau modulators and methods and compositions for their delivery
|
CN110494565A
(en)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
It is engineered B cell and compositions related and method
|
AU2017370644A1
(en)
|
2016-12-05 |
2019-06-13 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
US20200040345A1
(en)
|
2016-12-08 |
2020-02-06 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
US20200085758A1
(en)
|
2016-12-16 |
2020-03-19 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
US11920148B2
(en)
|
2017-02-22 |
2024-03-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
WO2018195418A1
(en)
|
2017-04-20 |
2018-10-25 |
Oregon Health & Science University |
Human gene correction
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
MX2020004907A
(en)
|
2017-11-09 |
2020-09-09 |
Sangamo Therapeutics Inc |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene.
|
US10940171B2
(en)
|
2017-11-10 |
2021-03-09 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
US10953036B2
(en)
|
2017-11-20 |
2021-03-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of modulating HIF-2A to improve muscle generation and repair
|
IL275177B1
(en)
|
2017-12-22 |
2024-01-01 |
Fate Therapeutics Inc |
Enhanced immune effector cells and use thereof
|
KR20200109358A
(en)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
DNA-PK inhibitor
|
JP2021511312A
(en)
|
2018-01-17 |
2021-05-06 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Kinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
AU2019209293B2
(en)
|
2018-01-17 |
2023-07-27 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
RU2020129448A
(en)
|
2018-02-08 |
2022-03-09 |
Сангамо Терапьютикс, Инк. |
DESIGNED TARGET-SPECIFIC NUCLEASE
|
SG11202008977UA
(en)
|
2018-03-29 |
2020-10-29 |
Fate Therapeutics Inc |
Engineered immune effector cells and use thereof
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
KR20210020873A
(en)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ cells expressing recombinant receptors, related polynucleotides and methods
|
MA52193A
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
T-LYMPHOCYTE RECEPTORS AND MODIFIED CELLS EXPRESSING THEM
|
EP3781587A4
(en)
|
2018-04-18 |
2022-03-30 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
JP2021522820A
(en)
|
2018-05-11 |
2021-09-02 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Methods and compositions for treating cancer
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
GB201809273D0
(en)
|
2018-06-06 |
2018-07-25 |
Vib Vzw |
Novel mutant plant cinnamoyl-coa reductase proteins
|
CA3102975A1
(en)
|
2018-06-07 |
2019-12-12 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Methods of regenerating and transforming cannabis
|
WO2019234754A1
(en)
|
2018-06-07 |
2019-12-12 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Nucleic acid constructs and methods of using same
|
WO2020028617A1
(en)
|
2018-08-01 |
2020-02-06 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
US11834686B2
(en)
|
2018-08-23 |
2023-12-05 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
WO2020047353A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
WO2020061161A1
(en)
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
SG11202104631SA
(en)
|
2018-11-07 |
2021-06-29 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
US20220226375A1
(en)
|
2018-11-07 |
2022-07-21 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
US20210292429A1
(en)
|
2018-11-07 |
2021-09-23 |
Crispr Therapeutics Ag |
Anti-liv1 immune cell cancer therapy
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
EA202191555A1
(en)
|
2018-12-05 |
2021-09-03 |
Вертекс Фармасьютикалз Инкорпорейтед |
GENE EDITING SYSTEMS FOR EDITING THE TRANSMEMBRANE FLUISCIDOSIS REGULATOR (CFTR) GENE
|
GB201820109D0
(en)
|
2018-12-11 |
2019-01-23 |
Vib Vzw |
Plants with a lignin trait and udp-glycosyltransferase mutation
|
AU2020205717A1
(en)
|
2019-01-11 |
2021-08-12 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
EP3914708A1
(en)
|
2019-01-24 |
2021-12-01 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
CN112805026A
(en)
|
2019-02-06 |
2021-05-14 |
桑格摩生物治疗股份有限公司 |
Methods for treating mucopolysaccharidosis type I
|
KR20210148106A
(en)
|
2019-03-08 |
2021-12-07 |
옵시디안 테라퓨틱스, 인크. |
CD40L compositions and methods for tunable modulation
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
CN113766921A
(en)
|
2019-04-23 |
2021-12-07 |
桑格摩生物治疗股份有限公司 |
Regulator for chromosome 9 open reading frame 72 gene expression and its use
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
KR20220016475A
(en)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
CA3144871A1
(en)
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
JP2022543112A
(en)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー,インコーポレイテッド |
DUX4-expressing cells and their uses
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
AU2020336992A1
(en)
|
2019-08-30 |
2022-04-14 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
AU2020343516A1
(en)
|
2019-09-06 |
2022-03-10 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
CN114466867A
(en)
|
2019-10-02 |
2022-05-10 |
桑格摩生物治疗股份有限公司 |
Zinc finger protein transcription factor for inhibiting alpha-synuclein expression
|
WO2021067864A1
(en)
|
2019-10-02 |
2021-04-08 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for treatment of prion disease
|
CA3159620A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
MX2022008415A
(en)
|
2020-01-08 |
2022-08-08 |
Obsidian Therapeutics Inc |
Compositions and methods for tunable regulation of transcription.
|
WO2021151012A1
(en)
|
2020-01-22 |
2021-07-29 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing tau expression
|
EP4097124A1
(en)
|
2020-01-28 |
2022-12-07 |
The Broad Institute Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
IL296665A
(en)
|
2020-03-25 |
2022-11-01 |
Sana Biotechnology Inc |
Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
|
CN115803435A
(en)
|
2020-05-06 |
2023-03-14 |
塞勒克提斯公司 |
Method for targeted insertion of foreign sequences in the genome of a cell
|
WO2021224416A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
KR20230022868A
(en)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Method for producing donor-batch cells expressing a recombinant acceptor
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
JP2023531531A
(en)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
US20230265214A1
(en)
|
2020-08-31 |
2023-08-24 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
MX2023003365A
(en)
|
2020-09-23 |
2023-03-29 |
Crispr Therapeutics Ag |
Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence.
|
JP2023542705A
(en)
|
2020-09-25 |
2023-10-11 |
サンガモ セラピューティクス, インコーポレイテッド |
Zinc finger fusion proteins for nucleobase editing
|
WO2022072826A1
(en)
|
2020-10-02 |
2022-04-07 |
Sangamo Therapeutics, Inc. |
Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
CN117042600A
(en)
|
2020-11-16 |
2023-11-10 |
猪改良英国有限公司 |
Anti-influenza a animals with edited ANP32 gene
|
CA3201621A1
(en)
|
2020-12-03 |
2022-06-09 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022137181A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
AU2021412988A1
(en)
|
2020-12-31 |
2023-06-15 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
AU2022207981A1
(en)
|
2021-01-12 |
2023-07-27 |
March Therapeutics, Inc. |
Context-dependent, double-stranded dna-specific deaminases and uses thereof
|
EP4305153A1
(en)
|
2021-03-09 |
2024-01-17 |
CRISPR Therapeutics AG |
Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
|
WO2022204071A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
CN117441010A
(en)
|
2021-04-07 |
2024-01-23 |
世纪治疗股份有限公司 |
Compositions and methods for producing alpha-beta T cells from induced pluripotent stem cells
|
WO2022216524A1
(en)
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
|
EP4320227A1
(en)
|
2021-04-07 |
2024-02-14 |
Century Therapeutics, Inc. |
Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
|
AU2022269643A1
(en)
|
2021-05-05 |
2023-11-02 |
FUJIFILM Cellular Dynamics, Inc. |
Methods and compositions for ipsc-derived microglia
|
KR20240011831A
(en)
|
2021-05-26 |
2024-01-26 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
Methods for preventing rapid silencing of genes in pluripotent stem cells
|
CA3216346A1
(en)
|
2021-05-27 |
2022-12-01 |
Edward Rebar |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
TW202321435A
(en)
|
2021-08-11 |
2023-06-01 |
美商薩那生物科技公司 |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
US20230183644A1
(en)
|
2021-09-10 |
2023-06-15 |
FUJIFILM Cellular Dynamics, Inc. |
Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
|
WO2023042079A1
(en)
|
2021-09-14 |
2023-03-23 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
WO2023070019A1
(en)
|
2021-10-21 |
2023-04-27 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
WO2023077050A1
(en)
|
2021-10-29 |
2023-05-04 |
FUJIFILM Cellular Dynamics, Inc. |
Dopaminergic neurons comprising mutations and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
US20230346836A1
(en)
|
2021-12-22 |
2023-11-02 |
Crispr Therapeutics Ag |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
WO2023122722A1
(en)
|
2021-12-22 |
2023-06-29 |
Sangamo Therapeutics, Inc. |
Novel zinc finger fusion proteins for nucleobase editing
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023129937A1
(en)
|
2021-12-29 |
2023-07-06 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
|
WO2023131616A1
(en)
|
2022-01-05 |
2023-07-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
TW202340457A
(en)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
Allogeneic therapeutic cells
|
US20230279376A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
US20230293646A1
(en)
|
2022-03-21 |
2023-09-21 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
TW202400778A
(en)
|
2022-03-23 |
2024-01-01 |
瑞士商Crispr治療公司 |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023240169A1
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
|
WO2023240147A1
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
|
WO2023240212A2
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
|
WO2023242827A2
(en)
|
2022-06-17 |
2023-12-21 |
Crispr Therapeutics Ag |
LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
|
WO2023248145A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Compositions and methods for treating human immunodeficiency virus
|
WO2023248147A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Methods and compositions for in vivo editing of stem cells
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024003786A1
(en)
|
2022-06-29 |
2024-01-04 |
Crispr Therapeutics Ag |
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
|
US20240003871A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Ipsc-derived astrocytes and methods of use thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024020597A1
(en)
|
2022-07-22 |
2024-01-25 |
The Johns Hopkins University |
Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|